

MONDAY, JUNE 15, 2009

**PLENARY SESSION I**  
AUDITORIUM

**Inhibitors of Cholesterol Synthesis and Atherosclerosis**

*Chairs: AM Gotto, Jr. (New York, NY, USA), A Alberts (Wyckoff, NJ, USA), T Miettinen (Helsinki, Finland), CP Cannon (Boston, MA, USA)*

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
8:00 AM - 8:20 AM	CHOLESTEROL BIOSYNTHESIS AND THE DISCOVERY OF STATINS <i>A Endo (Tokyo, Japan)</i>	17
8:20 AM - 8:30 AM	COMMENTARY <i>A Alberts (Wyckoff, NJ, USA)</i>	-
8:30 AM - 8:50 AM	CLINICAL USE OF STATINS <i>H Mabuchi (Kanazawa, Japan)</i>	18
8:50 AM - 9:00 AM	COMMENTARY <i>T Miettinen (Helsinki, Finland)</i>	-
9:00 AM - 9:20 AM	STATINS IN THE SECONDARY PREVENTION OF HEART DISEASE <i>TR Pedersen (Oslo, Norway)</i>	19
9:20 AM - 9:30 AM	COMMENTARY <i>CP Cannon (Boston, MA, USA)</i>	-
9:30 AM - 9:50 AM	PREVENTING THE FIRST MYOCARDIAL INFARCTION. ROLE OF STATINS <i>J Shepherd (Glasgow, UK)</i>	20
9:50 AM - 10:00 AM	COMMENTARY AND SESSION CONCLUSIONS <i>AM Gotto, Jr. (New York, NY, USA)</i>	-

**CLINICAL SYMPOSIUM I**  
AUDITORIUM

**New Developments in Statin Therapy**

*Chair: AM Gotto, Jr. (New York, NY, USA)*

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
10:30 AM - 10:55 AM	STATIN STRUCTURE FUNCTION DIFFERENCES <i>A Corsini (Milan, Italy)</i>	21
10:55 AM - 11:20 AM	EFFICACY OF STATINS <i>JJP Kastelein (Amsterdam, The Netherlands)</i>	22
11:20 AM - 11:45 AM	CLINICAL RESULTS WITH NEW STATINS <i>J Sasaki (Fukuoka, Japan)</i>	23
11:45 AM - 12:00 PM	CONCLUDING REMARKS <i>AM Gotto, Jr. (New York, NY, USA)</i>	-

**WORKSHOP I-1**  
BALLROOM B

**Intervention Studies: Statins in Primary and Secondary Prevention**

*Chairs: C Packard (Glasgow, UK), J Davignon (Montreal, QC, Canada)*

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
10:30 AM - 10:45 AM	LDL LOWERING AND BEYOND IN CHD PREVENTION <i>C Packard (Glasgow, UK)</i>	<b>24</b>
10:45 AM - 11:00 AM	UNTANGLING THE LIPID AND NON-LIPID EFFECTS OF STATINS ON CORONARY ARTERY DISEASE RISK <i>J Davignon (Montreal, QC, Canada)</i>	<b>25</b>
11:00 AM - 11:15 AM	HIGH-DOSE ATORVASTATIN PROVIDES SUSTAINED BENEFIT IN REDUCING RISK OF CV DISEASE AMONG STABLE CHD PATIENTS ≥65 YEARS <i>N Wenger, J LaRosa, J Shepherd (Atlanta, GA, USA, New York, NY, USA and Glasgow, UK)</i>	<b>26</b>
11:15 AM - 11:30 AM	IMPACT OF XUEZHUKANG ON CORONARY EVENTS IN HYPERTENSIVE PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION (CCSPS STUDY) <i>J-J Li, Z-L Lu, W-R Kou, Z Chen, Y-F Wu, X-H Yu, Y-C Zhao, P Nimoiytn, D Capuzzi (Beijing, China and Philadelphia, PA, USA)</i>	<b>27</b>
11:30 AM - 11:45 AM	CONSISTENCY BETWEEN LIPID LOWERING AND REDUCTION OF ISCHEMIC CARDIOVASCULAR EVENTS (ICE) IN THE SIMVASTATIN AND EZETIMIBE IN AORTIC STENOSIS (SEAS) TRIAL <i>I Holme, A Rossebø, T Pedersen (Oslo, Norway)</i>	<b>28</b>
11:45 AM - 12:00 PM	THE DIFFERENT LIPID LOWERING TARGET BY STATINS FOR JAPANESE TO PREVENT CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTIONS <i>T Sakamoto, H Ogawa (Kumamoto, Japan)</i>	<b>29</b>
12:00 PM - 12:15 PM	THE EFFECT OF PRAVASTATIN IN THE PATIENTS WITH CHRONIC KIDNEY DISEASE COMBINED WITH METABOLIC SYNDROME IN PRIMARY PREVENTION: A POST HOC ANALYSIS OF MEGA STUDY <i>H Nakamura, K Mizuno (Tokyo, Japan)</i>	<b>30</b>
12:15 PM - 12:30 PM	EZETIMIBE/SIMVASTATIN (E/S) VS ATORVASTATIN (A) IN METABOLIC SYNDROME (MS) PATIENTS WITH HYPERCHOLESTEROLEMIA (HC) <i>J Robinson, C Ballantyne, S Grundy, W Hsueh, H-H Parving, J Rosen, A Adewale, A Polis, J Tomassini, A Tershakovec (Iowa City, IA, USA, Houston, TX, USA, Dallas, TX, USA, Copenhagen, Denmark, Coral Gables, FL, USA and N Wales, PA, USA)</i>	<b>31</b>

WORKSHOP I-2  
BALLROOM A

**Pharmacology and Novel Therapies: Statin Pharmacogenetics**

Chairs: **K Kajinami** (Uchinada, Japan), **R Krauss** (Oakland, CA, USA)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	UNDERSTANDING GENETIC EFFECTS ON LIPID-LOWERING WITH STATIN THERAPY: FROM CANDIDATE GENES FOR LDL-C REDUCTION TO WHOLE GENOME ANALYSIS OF 22 LIPOPROTEIN FRACTIONS AT BASELINE <b>D Chasman</b> (Boston, MA, USA)	32
10:45 AM - 11:00 AM	STATIN PHARMACOGENOMICS: ROLE OF COMBINED ANALYSIS OF FUNCTIONALLY-RELATED LOCI <b>K Kajinami, R Sato, H Akao, E Schaefer</b> (Uchinada, Japan and Boston, MA, USA)	33
11:00 AM - 11:15 AM	ION MOBILITY ANALYSIS OF LIPOPROTEIN SUBFRACTIONS SUGGESTS THREE INDEPENDENT MECHANISMS OF CARDIOVASCULAR RISK <b>K Musumuru, M Orho-Melander, M Caulfield, R Reitz, G Berglund, B Hedblad, G Engstrom, S Kathiresan, O Melander, R Krauss</b> (Boston, MA, USA, Malmö, Sweden, Cambridge, MA, USA and Oakland, CA, USA)	34
11:15 AM - 11:30 AM	GENE VARIANTS AND PRAVASTATIN LDL LOWERING RESPONSE IN PROSPER <b>E Polisecki, M Robertson, J Shepherd, C Packard, JW Jukema, I Peter, T Van Himbergen, E Schaefer</b> (Boston, MA, USA, Glasgow, UK, Cork, Ireland, Leiden, The Netherlands and New York, NY, USA)	35
11:30 AM - 11:45 AM	EFFECTS OF GENETIC VARIANTS IN DRUG METABOLIZING ENZYMES AND TRANSPORTERS ON STATIN SAFETY AND EFFICACY <b>B Tomlinson, M Hu, V Mak, T Chu, V Lee</b> (Shatin, Hong Kong)	36
11:45 AM - 12:00 PM	PHYSIOGENOMIC CONTOURS OF STATIN SAFETY AND EFFICACY <b>G Rúaño, P Thompson, J Kane, C Pullinger, A Windemuth, B Gordon, R Seip, M Kocherla, A Wu</b> (Hartford, CT, USA, San Francisco, CA, USA and New York, NY, USA)	37
12:00 PM - 12:15 PM	PITAVASTATIN IMPROVES THE KIDNEY FUNCTION IN ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL PATIENTS WITH MILD IMPAIRMENT OF KIDNEY FUNCTION <b>J Kanda</b> (Asahi, Japan)	38
12:15 PM - 12:30 PM	ROLE OF RHO-KINASE IN THE PATHOGENESIS OF CORONARY HYPERCONSTRUCTING RESPONSES INDUCED BY PACLITAXEL-ELUTING STENT <b>T Shiroto, S Yasuda, R Tsuburaya, Y Ito, J Takahashi, K Ito, H Ishibashi-Ueda, H Shimokawa</b> (Sendai, Japan and Suita, Japan)	39

MONDAY, JUNE 15, 2009

**WORKSHOP I-3A**  
BALLROOM C

**Epidemiology of Cardiovascular Disease: Heart Disease Worldwide**

*Chairs: S Reddy (New Delhi, India) J Zhu (Shanghai, China)*

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
10:30 AM - 10:45 AM	CARDIOVASCULAR DISEASES IN LOW AND MIDDLE INCOME COUNTRIES: DIMENSIONS, DETERMINANTS AND DYNAMICS OF HEALTH TRANSITION <i>S Reddy (New Delhi, India)</i>	40
10:45 AM - 11:00 AM	GLOBAL BURDEN OF CARDIOVASCULAR DISEASE: AN OVERVIEW <i>J Zhu (Shanghai, China)</i>	41
11:00 AM - 11:15 AM	WORLDWIDE N-3 FATTY ACID INSUFFICIENCY: IS IT RELATED TO CVD? <i>H Campos, W Zatonski (Boston, MA, USA and Warsaw, Poland)</i>	42

**WORKSHOP I-3B**  
BALLROOM C

**A Unique and Global Initiative: The Residual Reduction Risk Initiative (R<sup>2</sup>i)**

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
11:15 AM - 11:45 AM	THE RESIDUAL REDUCTION RISK INITIATIVE: ADDRESSING A MAJOR CHALLENGE FOR HEALTHCARE <i>J-C Fruchart (Lille, France)</i>	1520
11:45 AM - 12:15 PM	NON-LDL-RELATED DYSLIPIDEMIA AND CORONARY RISK <i>G Assmann (Münster, Germany)</i>	1519

Monday,  
June 15

WORKSHOP I-4  
ROOM 302

**Genetics: Familial Hyperlipidemia**

Chairs: **J de Graaf** (Nijmegen, The Netherlands), **F Civeira** (Zaragoza, Spain)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	CLINICAL PRACTICE: A DIAGNOSTIC ALGORITHM FOR ATHEROGENIC APOB DYSLIPOPROTEINEMIAS <b>J de Graaf</b> (Nijmegen, The Netherlands)	<b>43</b>
10:45 AM - 11:00 AM	CONTRIBUTION OF LDL RECEPTOR GENE MUTATIONS TO DIFFERENT HYPERCHOLESTEROLEMIA PHENOTYPES <b>F Civeira</b> (Zaragoza, Spain)	<b>44</b>
11:00 AM - 11:15 AM	CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH FAMILIAL LIPID DISORDERS <b>PN Hopkins</b> (Salt Lake City, UT, USA)	<b>45</b>
11:15 AM - 11:30 AM	COMPARISON OF CAROTID INTIMA-MEDIA THICKNESS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA AND FAMILIAL COMBINED HYPERLIPIDEMIA <b>E Jarauta, R Mateo, A Bea, S Fiddymnt, E Burillo, F Civeira</b> (Zaragoza, Spain)	<b>46</b> <b>YIA</b>
11:30 AM - 11:45 AM	EVIDENCE OF INCREASED CHOLESTEROL SYNTHESIS IN FAMILIAL COMBINED HYPERLIPIDEMIA <b>T van Himbergen, E Schaefer, N Matthan, J de Graaf, A Stalenhoef</b> (Boston, MA, USA and Nijmegen, The Netherlands)	<b>47</b> <b>YIA</b>
11:45 AM - 12:00 PM	PHENOTYPE AND GENOTYPE OF FAMILIAL HYPERCHOLESTEROLEMIA IN OVER 2000 CHILDREN <b>A van der Graaf, H Avis, M Vissers, B Hutten, J Defesche, A Wiegman, S Fouchier, J Kastelein</b> (Amsterdam, The Netherlands)	<b>48</b> <b>YIA</b>
12:00 PM - 12:15 PM	CROSS-SPECIES COMPARISONS OF GWAS DATA AS A SCREENING TOOL TO IDENTIFY NOVEL LOCI FOR LDL-C <b>C PI, B Haas, M Laakso, P Pajukanta</b> (Los Angeles, CA, USA and Kuopio, Finland)	<b>49</b>
12:15 PM - 12:30 PM	THE FIRST REPORT OF THE TREATMENT OF TRANSPLANT CORONARY ARTERY DISEASE WITH DSA LIPID APHERESIS <b>R Sosland, S Gollub, P Moriarty</b> (Kansas City, KS, USA)	<b>50</b> <b>YIA</b>

WORKSHOP I-5  
ROOM 312

**Nutritional Studies: Dietary Fatty Acids**

Chairs: **BV Howard** (Hyattsville, MD, USA), **LL Rudel** (Winston-Salem, NC, USA)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	IMPACT OF ANIMAL VERSUS INDUSTRIAL TRANS FATTY ACIDS ON LIPOPROTEINS IN HUMANS <b>MB Katan</b> , A Wanders, I Brouwer, E Siebelink (Amsterdam, The Netherlands)	51
10:45 AM - 11:00 AM	LESSONS FROM THE DIET TRIAL OF THE WOMEN'S HEALTH INITIATIVE <b>BV Howard</b> (Hyattsville, MD, USA and Washington, DC, USA)	52
11:00 AM - 11:15 AM	DIETARY UNSATURATED FATTY ACIDS ARE UNIQUE IN EFFECTIVENESS IN ATHEROPROTECTION <b>C Degirolamo</b> , L Rudel, T Bell III (Winston-Salem, NC, USA)	53
11:15 AM - 11:30 AM	EFFECTS OF A HIGH INTAKE OF CONJUGATED LINOLEIC ACID, A RUMINANT TRANS FATTY ACID, ON LIPOPROTEINS AND INFLAMMATION MARKERS IN HUMANS A Wanders, <b>I Brouwer</b> , E Siebelink, M Katan (Amsterdam, The Netherlands and Wageningen, The Netherlands)	54
11:30 AM - 11:45 AM	VALIDATION OF THE MedDietSCORE THROUGH PLASMA FATTY ACIDS <b>D Panagiotakos</b> , N Kalogeropoulos, C Pitsavos, C Stefanadis (Athens, Greece)	55
11:45 AM - 12:00 PM	COMPOSITION OF PLASMA AND PLAQUE AMONG CORONARY ARTERY DISEASE SUBJECTS CONSUMING COCONUT OIL/SUNFLOWER OIL <b>S Palazhy</b> , M Vasudevan, K Vaidyanathan, P Kamath (Kerala, India)	56 YIA
12:00 PM - 12:15 PM	DIETARY POLYUNSATURATED FATTY ACIDS INDUCE LESS ABCA1 AND MACROPHAGE EXPRESSION IN THE AORTA OF LDLR-KO MICE THAN TRANS AND SATURATED FATTY ACIDS <b>R Machado</b> , E Nakandakare, E Quintão, F Ferreira, V Nunes, P Cazita, S Catanozi, AM Lottenberg (São Paulo, Brazil)	57
12:15 PM - 12:30 PM	MODERATE FISH CONSUMPTION IS ASSOCIATED WITH LOWER LIKELIHOOD OF DEVELOPING LEFT VENTRICULAR SYSTOLIC DYSFUNCTION, IN ACUTE CORONARY SYNDROME PATIENTS <b>C-M Kistorini</b> , C Chrysohoou, D Panagiotakos, P Aggelopoulos, C Liontou, I Skoumas, C Pitsavos, C Stefanadis (Athens, Greece)	58

WORKSHOP I-6  
ROOM 304

**Imaging of Atherosclerosis: The Vulnerable Plaque**

Chairs: **J Muller** (Burlington, MA, USA), **R Virmani** (Gaithersburg, MD, USA)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	CONSEQUENCES OF ENDOTHELIAL PHENOTYPIC DRIFT DURING PLAQUE PROGRESSION <i>AJ Horrevoets</i> (Amsterdam, The Netherlands)	<b>59</b>
10:45 AM - 11:00 AM	PATHOLOGY, DETECTION AND TREATMENT OF VULNERABLE PLAQUE <i>S Madden, J Muller</i> (Burlington, MA, USA)	<b>60</b>
11:00 AM - 11:15 AM	IMAGING ATHEROSCLEROTIC PLAQUE INFLAMMATION <i>JH Rudd</i> (Cambridge, UK)	<b>61</b>
11:15 AM - 11:30 AM	CRITICAL PATHOLOGIC EVALUATION OF WHAT CONSTITUTES A VULNERABLE PLAQUE <i>R Virmani</i> (Gaithersburg, MD, USA)	<b>62</b>
11:30 AM - 11:45 AM	PSGL-1 IS A KEY MOLECULE FOR PLAQUE STABILITY IN ACUTE CORONARY SYNDROME <i>K Gomita, K Sato, M Sawabe, N Hagiwara</i> (Tokyo, Japan)	<b>63</b> <b>YIA</b>
11:45 AM - 12:00 PM	LYSYL-OXIDASE-DEPENDENT EXTRACELLULAR MATURATION OF COLLAGEN IS REDUCED IN HYPERINFLAMED ATHEROSCLEROTIC PLAQUES OF <i>ApoE</i> <sup>-/-</sup> MICE <i>O Ovchinnikova, A-K Robertson, D Wågsäter, E Folco, M Hyry, J Myllyharju, P Eriksson, N Gavrisheva, E Shlyakhto, P Libby, G Hansson</i> (Stockholm, Sweden, St. Petersburg, Russian Federation, Boston, MA, USA and Oulu, Finland)	<b>64</b> <b>YIA</b>
12:00 PM - 12:15 PM	CHOLESTEROL-LOWERING THERAPY WITH THE CHOLESTEROL ABSORPTION INHIBITOR EZETIMIBE INHIBITS PLAQUE DESTABILIZATION AND RUPTURE IN THE BRACHIOCEPHALIC ARTERIES OF <i>ApoE</i> -DEFICIENT MICE <i>K Sato, T Matoba, K Egashira</i> (Fukuoka, Japan)	<b>65</b> <b>YIA</b>
12:30 PM - 12:45 PM	<i>Withdrawn</i>	<b>66</b>

WORKSHOP I-7  
ROOM 310

**Lipoprotein Metabolism: Joint IAS-EAS Workshop "Hepatic Apolipoprotein B Metabolism"**

Chairs: **HN Ginsberg** (New York, NY, USA), **M-R Taskinen** (Helsinki, Finland)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	CHARACTERISTICS OF CIRCULATING VLDL RESULTING FROM INSULIN RESISTANCE AND FATTY LIVER <b>LL Schreier</b> (Buenos Aires, Argentina)	67
10:45 AM - 11:00 AM	REGULATION OF VLDL ASSEMBLY AND SECRETION BY LIPIDS, INSULIN, AND ER STRESS <b>HN Ginsberg</b> (New York, NY, USA)	68
11:00 AM - 11:15 AM	IS HEPATIC STEATOSIS THE CULPRIT OF DYSLIPIDEMIA IN SUBJECTS WITH ABDOMINAL OBESITY? <b>M-R Taskinen, M Adiels, S Söderlund, N Lundbom, V Di Marzo, J Borén</b> (Helsinki, Finland, Gothenburg, Sweden and Pozzuoli, Italy)	69
11:15 AM - 11:30 AM	CHANGES IN LIPOPROTEIN COPOSITION IN DIABETIC DYSLIPIDEMIA <b>M Ståhlman, A Hiukka, M-R Taskinen, K Ekroos, J Borén</b> (Gothenburg, Sweden, Helsinki, Finland and Espoo, Finland)	70
11:30 AM - 11:45 AM	ABNORMAL HEPATIC APOLIPROTEIN B METABOLISM IN TYPE 2 DIABETES <b>B Vergès</b> (Dijon, France)	71
11:45 AM - 12:00 PM	EFFECT OF A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) BETA/DELTA AGONIST ON LIPOPROTEIN KINETICS IN THE METABOLIC SYNDROME <b>E Ooi, G Watts, B Staels, S Caron, D Sprecher, H Barrett</b> (Perth, Australia, Lille, France and King of Prussia, PA, USA)	72
12:00 PM - 12:15 PM	GENE EXPRESSION PROFILING OF NUCLEAR RECEPTORS IN MOUSE LIVER PARENCHYMAL, ENDOTHELIAL, AND KUPFFER CELLS <b>Z Li, M Hoekstra, JK Kruijt, T Van Berkel</b> (Leiden, The Netherlands)	73 YIA
12:15 PM - 12:30 PM	ASP-C5L2 KO MICE DO NOT HAVE INCREASED HEPATIC LIPOPROTEIN PRODUCTION <b>A Fiset, S Pagliarunga, K Cianflone</b> (Quebec, QC, Canada)	74

WORKSHOP I-8

Room 311

**Basic Science and Vascular Biology: Oxidative Stress**

Chairs: **JL Witztum** (La Jolla, CA, USA), **M Kitakaze** (Suita, Japan)

Time	Presentation	Publication No.
10:30 AM - 10:45 AM	HDL – ASSOCIATED PARAOXONASE 1 (PON1) ATTENUATES MACROPHAGE FOAM CELL FORMATION <i>M Aviram</i> (Haifa, Israel)	75
10:45 AM - 11:00 AM	THE ONSET OF ACUTE CORONARY SYNDROME IS ATTRIBUTABLE TO ENDOPLASMIC RETICULUM STRESS IN ATHEROSCLEROTIC PLAQUES <i>M Kitakaze, M Myoishi, O Tsukamoto, N Hashimoto, H Tomoike</i> (Suita, Japan)	76
11:00 AM - 11:15 AM	RHO-KINASE IS AN IMPORTANT THERAPEUTIC TARGET IN CARDIOVASCULAR MEDICINE <i>H Shimokawa</i> (Sendai, Japan)	77
11:15 AM - 11:30 AM	THE ROLE OF OXIDIZED PHOSPHOLIPIDS IN MEDIATING LIPOPROTEIN(a) ATHEROGENICITY <i>JL Witztum</i> (La Jolla, CA, USA)	*78
11:30 AM - 11:45 AM	SUPEROXIDE-DEPENDENT CATHEPSIN ACTIVATION SYSTEM IS ASSOCIATED WITH HYPERTENSIVE RENAL REMODELING AND REPRESENTS A TARGET FOR STATIN TREATMENT <i>XW Cheng, K Okumura, T Sasaki, M Kuzuya, T Murohara</i> (Nagoya, Japan)	79
11:45 AM - 12:00 PM	PROTEOMIC ANALYSIS OF DEFINED HDL SUBPOPULATIONS REVEALS PARTICLE-SPECIFIC PROTEIN CLUSTERS: RELEVANCE TO ANTIOXIDATIVE FUNCTION <i>W Davidson, R Silva, S Chantepie, W Lagor, M Chapman, A Kontush</i> (Cincinnati, OH, USA and Paris, France)	80
12:00 PM - 12:15 PM	PROTECTION AGAINST ATHEROSCLEROSIS BY HEME OXYGENASE-1 <i>C Li, B Wu, R Midwinter, K Beck, E Collinson, G Maghzal, C Cassano, F Santiago, L Khachigian, J Gamble, R Stocker</i> (Sydney, Australia)	81
12:15 PM - 12:30 PM	MECHANISMS IMPLICATED IN THE POTENT PROTECTION OF LDL FROM OXIDATIVE STRESS MEDIATED BY SMALL, DENSE HDL3 <i>A Zerrad-Saadi, P Therond, M Couturier, S Chantepie, K Rye, M Chapman, A Kontush</i> (Paris, France and Sydney, Australia)	82 YIA
12:30 PM - 12:45 PM	MiR-217 REGULATES AGING AND ANGIOGENIC FUNCTIONS IN HUMAN ENDOTHELIUM VIA SIRT1 <i>R Menghini, V Casagrande, M Cardellini, F Amati, A Terrinoni, A Marino, E Martelli, A Ippoliti, G Melino, G Novelli, R Lauro, M Federici</i> (Rome, Italy)	564

MONDAY, JUNE 15, 2009

**MASTER SESSION I**  
BALLROOM B

**Difficulties of Drug Development**  
*Chair: R Paoletti (Milan, Italy)*

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
1:30 PM - 1:45 PM	CANNABINOID RECEPTOR BLOCKERS <i>J-P Després (Quebec, QC, Canada)</i>	83
1:45 PM - 2:00 PM	MICROSOMAL TRANSFER PROTEIN INHIBITORS <i>RE Gregg (Ft. Washington, PA, USA)</i>	84
2:00 PM - 2:15 PM	STATINS <i>A Alberts (Wyckoff, NJ, USA)</i>	85
2:15 PM - 2:30 PM	CETP INHIBITORS <i>PJ Barter (Sydney, Australia)</i>	86
2:30 PM - 2:45 PM	CONCLUDING REMARKS <i>R Paoletti (Milan, Italy)</i>	-

**MASTER SESSION II**  
BALLROOM A

**The Discovery of Lipoprotein Receptors and Their Role in Atherosclerosis**

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
1:30 PM - 2:15 PM	THE DISCOVERY OF LIPOPROTEIN RECEPTORS AND THEIR ROLE IN ATHEROSCLEROSIS <i>M Krieger (Cambridge, MA, USA)</i>	87
2:15 PM - 2:30 PM	COMMENTARY <i>U Beisiegel (Hamburg, Germany)</i>	-

MONDAY, JUNE 15, 2009

CLINICAL SYMPOSIUM II  
AUDITORIUM

**Effects of Statin Therapy on the Carotid Artery, Coronary Atheromas, and  
Coronary Heart Disease Prevention**

*Chair: P Jones (Houston, TX, USA)*

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
1:30 PM - 1:55 PM	EFFECTS OF STATIN THERAPY ON THE CAROTID ARTERY <i>JR Crouse (Winston Salem, NC, USA)</i>	88
1:55 PM - 2:20 PM	CORONARY ATHEROMA <i>SJ Nicholls (Cleveland, OH, USA)</i>	89
2:20 PM - 2:45 PM	PRIMARY PREVENTION OF HEART DISEASE <i>PM Ridker (Boston, MA, USA)</i>	90
2:45 PM - 3:00 PM	CONCLUDING REMARKS <i>P Jones (Houston, TX, USA)</i>	-

WORKSHOP  
ROOM 312

**Calories From Beverages: An Underestimated Dietary  
Target for the Prevention/Management of Obesity/Type 2 Diabetes?**

*Chairs: J-P Després (Quebec, QC, Canada), E Horton (Boston, MA, USA)*

In partnership with the International Chair on Cardiometabolic Risk

---

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
	INTRODUCTION <i>E Horton (Boston, MA, USA)</i>	-
2:00 PM – 2:20 PM	GLOBAL DIMENSIONS OF SUGARY BEVERAGES AND PROGRAMMATIC AND POLICY SOLUTIONS <i>B Popkin (Chapel Hill, NC, USA)</i>	1521
2:20 PM – 2:40 PM	SOFT DRINKS AND OBESITY: THE EVIDENCE <i>G Bray (Baton Rouge, LA, USA)</i>	1522
2:40 PM – 3:00 PM	SUGAR-SWEETENED DRINKS AND TYPE 2 DIABETES <i>F Hu (Boston, MA, USA)</i>	*1523
	CONCLUSION <i>J-P Després (Quebec, QC, Canada)</i>	-

WORKSHOP II-1  
BALLROOM B

**Intervention Studies: Weight Loss Therapy**

Chairs: **F Rubino** (New York, NY, USA), **C Apovian** (Boston, MA, USA)

Time	Presentation	Publication No.
3:30 PM - 3:45 PM	FROM "BARIATRIC" TO "METABOLIC" SURGERY: MODERN SCIENCE VERSUS THE STIGMA OF OBESITY <b>F Rubino</b> (New York, NY, USA)	91
3:45 PM - 4:00 PM	DIET TYPE, PARTICIPATION, AND LONG-TERM WEIGHT LOSS <b>FM Sacks</b> (Boston, MA, USA)	*92
4:00 PM - 4:15 PM	TREATMENT OF OBESITY <b>C Apovian</b> (Boston, MA, USA)	93
4:15 PM - 4:30 PM	EFFECT OF WEIGHT LOSS ON HIGH DENSITY LIPOPROTEIN APOLIPOPROTEIN A-II KINETICS IN THE METABOLIC SYNDROME <b>T Ng, G Watts, H Barrett, D Chan</b> (Perth, Australia)	94
4:30 PM - 4:45 PM	LONG TERM EFFECTS OF WEIGHT LOSS FROM A VERY-LOW-CARBOHYDRATE DIET ON ENDOTHELIAL FUNCTION IN SUBJECTS WITH ABDOMINAL OBESITY <b>T Wycherley, G Brinkworth, M Noakes, J Keogh, J Buckley, P Clifton</b> (Adelaide, Australia)	95
4:45 PM - 5:00 PM	LDL-CHOLESTEROL LOWERING EITHER THROUGH THERAPEUTIC LIFESTYLE CHANGE INTERVENTION OR HMG-COA REDUCTASE INHIBITOR TREATMENT DECREASES MEAN PLATELET VOLUME VALUES IN PEOPLE WITH ELEVATED LDL-CHOLESTEROL <b>G Erdem, I Tasci, G Celebi, G Ozgur, T Dogru, A Sonmez, C Ercin, S Tapan</b> (Ankara, Turkey)	96
5:00 PM - 5:15 PM	CALORIC RESTRICTION STIMULATES ISCHEMIA-INDUCED ANGIOGENESIS VIA ADIPONECTIN-MEDIATED ACTIVATION OF eNOS <b>R Shibata, N Ouchi, K Walsh, T Murohara</b> (Nagoya, Japan and Boston, MA, USA)	97
5:15 PM - 5:30 PM	METABOLIC SURGERY FOR THE METABOLIC SYNDROME <b>H Buchwald</b> (Minneapolis, MN, USA)	98

WORKSHOP II-2  
BALLROOM A

**Pharmacology and Novel Therapies: Novel Therapies and Safety Aspects**

*Chairs: H Mabuchi (Kanazawa, Japan), PD Thompson (Hartford, CT, USA)*

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
3:30 PM - 3:45 PM	COENZYME Q10 REDUCTION WITH STATINS: ANOTHER PLEIOTROPIC EFFECT <i>H Mabuchi (Kanazawa, Japan)</i>	<b>99</b>
3:45 PM - 4:00 PM	STATIN MYALGIA <i>PD Thompson (Hartford, CT, USA)</i>	<b>100</b>
4:00 PM - 4:15 PM	PROPOSED EFFICACY CRITERIA AND CHOLESTEROL TARGETS FOR LDL APHERESIS <i>GR Thompson (London, UK)</i>	<b>101</b>
4:15 PM - 4:30 PM	THE EFFECT OF Q10 AND SELENIUM SUPPLEMENT ON ADVERSE EFFECTS IN STATIN TREATMENT <i>M Bogsrud, K Retterstøl, L Ose, U Malt, B Woldseth (Oslo, Norway)</i>	<b>102</b> <b>Y1A</b>
4:30 PM - 4:45 PM	EFFECTS OF LOW DOSE MTP INHIBITION ALONE AND IN COMBINATION WITH OTHER LIPID- LOWERING DRUGS ON HEPATIC FAT AND PLASMA LIPIDS <i>E Meagher, M Davidson, M Rosen, J Robinson, H Bays, L Bloedon, W Sasiela, M Parris, D Rader (Philadelphia, PA, USA, Chicago, IL, USA, Iowa City, IA, USA, Louisville, KY, USA and Bridgewater, NJ, USA)</i>	<b>103</b>
4:45 PM - 5:00 PM	EFFECT OF MIPOMERSEN TREATMENT ON HEPATIC TRIGLYCERIDE CONTENT IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA <i>M Visser, F Akdim, D Basart, J Kastelein, A Nederveen, T Kwoh, D Tribble, E Stroes (Amsterdam, The Netherlands, Hoorn, The Netherlands and Carlsbad, CA, USA)</i>	<b>104</b> <b>Y1A</b>
5:00 PM - 5:15 PM	INCREASED PLASMA CERAMIDES FOLLOW STATIN- INDUCED MUSCLE TOXICITY <i>R Laaksonen, G Mombelli, K Tarasov, D Kauhanen, K Koistinen, R Hurme, C Sirtori, K Ekroos (Espoo, Finland and Milan, Italy)</i>	<b>105</b>
5:15 PM - 5:30 PM	DEFICIENT ANTIOXIDATIVE ACTIVITY OF SMALL, DENSE HIGH-DENSITY LIPOPROTEINS (HDL3) IN FAMILIAL HYPERCHOLESTEROLEMIA (FH): THERAPEUTIC CORRECTION BY LDL APHERESIS <i>H Hussein, M Atassi-Dumont, S Saheb, S Chantepie, M Chapman, A Kontush (Paris, France)</i>	<b>106</b> <b>Y1A</b>
5:30 PM - 5:45 PM	LIPIDS APHERESIS BY IMMUNOSORBENTS IS THE EFFECTIVE METHODS FOR LDL AND LP(a) ELIMINATION <i>I Adamova, J Berestatskaya, G Kononov, S Baida, S Pokrovsky (Moscow, Russian Federation)</i>	<b>362</b>

WORKSHOP II-3  
BALLROOM C

**Epidemiology of Cardiovascular Disease: Global Risk Assessment**

Chairs: **RB D'Agostino** (Boston, MA, USA), **G Assmann** (Münster, Germany)

Time	Presentation	Publication No.
3:30 PM - 3:45 PM	EVALUATING THE IMPACT OF NEW MARKERS ON RISK PREDICTION <i>NR Cook</i> (Boston, MA, USA)	107
3:45 PM - 4:00 PM	CVD GLOBAL RISK MODELS: THE FRAMINGHAM EXPERIENCE <i>RB D'Agostino</i> (Boston, MA, USA)	108
4:00 PM - 4:15 PM	GLOBAL RISK ASSESSMENT FOR CARDIOVASCULAR DISEASE IN 2009 <i>PW Wilson</i> (Atlanta, GA, USA)	109
4:15 PM - 4:30 PM	VASCULAR RISK ASSESSMENT AND MANAGEMENT <i>DA Wood</i> (London, UK)	110
4:30 PM - 4:45 PM	THE PATIENT AT RISK FOR MYOCARDIAL INFARCTION AND STROKE: NEW PROCAM DATA <i>G Assmann</i> (Münster, Germany)	111
4:45 PM - 5:00 PM	COMMON CAROTID ARTERY DIAMETER AS A MARKER OF CARDIOVASCULAR RISK: PRELIMINARY RESULTS OF THE IMPROVE STUDY <i>M Amato, D Baldassarre, E Tremoli, IMPROVE Study Group</i> (Milan, Italy)	112
5:00 PM - 5:15 PM	PATIENTS WITH ATHEROSCLEROSIS MISSED BY FRAMINGHAM 10-YEAR RISK SCORING <i>A Doneen, B Bale, D Feng</i> (Spokane, WA, USA and Lubbock, TX, USA)	113
5:15 PM - 5:30 PM	CAROTID PLAQUE AND IMT IN THE POPULATION BASED REFINE REYKJAVIK STUDY IN CONTEXT WITH THE SHAPE GUIDELINES <i>V Gudnason, B Thorsson, S Sigurdsson, T Aspelund</i> (Kopavogur, Iceland)	114

WORKSHOP II-4  
ROOM 302

**Genetics: Genetics of High Density Lipoproteins**

Chairs: *A Tybjaerg-Hansen (Copenhagen, Denmark), ME Brousseau (Cambridge, MA, USA)*

Time	Presentation	Publication No.
3:30 PM - 3:45 PM	IDENTIFICATION OF SUSCEPTIBILITY LOCI FOR THE LOW HDL-C/CHD TRAIT <i>M Brousseau, S Demissie, G Peloso, L Cupples, S Gabriel, D Collins, D Mirel, E Schaefer (Boston, MA, USA, Cambridge, MA, USA and New Haven, CT, USA)</i>	115
3:45 PM - 4:00 PM	LECITHIN: CHOLESTEROL ACYLTRANSFERASE DEFICIENCY SYNDROMES <i>L Calabresi, G Franceschini (Milan, Italy)</i>	116
4:00 PM - 4:15 PM	DOES GENETIC VARIATION IN HDL GENES PREDICT RISK OF ISCHEMIC HEART DISEASE? <i>A Tybjaerg-Hansen (Copenhagen, Denmark)</i>	117
4:15 PM - 4:30 PM	WHERE ARE WE WITH THE GENETICS OF HDL? <i>JA Kuivenhoven (Amsterdam, The Netherlands)</i>	118
4:30 PM - 4:45 PM	MUTATION IN <i>APOA</i> PREDICTS INCREASED RISK OF ISCHEMIC HEART DISEASE AND EARLY DEATH WITHOUT LOW HDL CHOLESTEROL <i>C Lundegaard, R Frikke-Schmidt, B Nordestgaard, A Kateifides, D Kardassis, V Zannis, P Grande, A Tybjaerg-Hansen (Copenhagen, Denmark, Heraklion, Greece and Boston, MA, USA)</i>	119 Y1A
4:45 PM - 5:00 PM	STRUCTURAL AND FUNCTIONAL FEATURES OF HDL FROM CARRIERS OF THE R37X MUTATION IN CETP GENE <i>L Calabresi, E Favari, F Bernini, P Nilsson, C Sirtori, P Tarugi, G Franceschini, M Gomaraschi (Milan, Italy, Parma, Italy, Modena, Italy and Malmö, Sweden)</i>	120 Y1A
5:00 PM - 5:15 PM	GENOMIC SELECTION BY HYBRIDIZATION-ENRICHMENT FOR LARGE SCALE SEQUENCING OF GENES IMPLICATED IN HDL METABOLISM <i>GK Hovingh, D Herman, J Seidman (Amsterdam, The Netherlands and Boston, MA, USA)</i>	121 Y1A
5:15 PM - 5:30 PM	IDENTIFICATION OF NEW CANDIDATE GENES REGULATING LIPID LEVELS IN A QUANTITATIVE TRAIT LOCI ANALYSIS BETWEEN INBRED MOUSE STRAINS MRL/MPJ AND SM/J <i>M Leduc, S-W Tsaih, G Churchill, B Paigen (Bar Harbor, ME, USA)</i>	122

WORKSHOP II-5  
ROOM 312

**The Metabolic Syndrome and its Implications for Global Cardiometabolic Risk Assessment/Management**

Chairs: **P Libby** (Boston, MA, USA), **J-P Després** (Quebec, QC, Canada)

In partnership with the International Chair on Cardiometabolic Risk

Time	Presentation	Publication No.
3:30 PM - 3:35 PM	OPENING REMARKS <b>P Libby</b> (Boston, MA, USA)	-
3:35 PM - 3:55 PM	IS THE CONCEPT OF METABOLIC SYNDROME HELPFUL? <b>NJ Stone</b> (Chicago, IL, USA)	123
3:55PM - 4:15 PM	PATHOPHYSIOLOGY OF METABOLIC SYNDROME AND RELATED GLOBAL CARDIOMETABOLIC RISK. WHAT'S NEW? <b>J Plutzky</b> (Boston, MA, USA)	124
4:15 PM - 4:35 PM	ABDOMINAL OBESITY AND METABOLIC SYNDROME IN CARDIOLOGY: CLINICAL IMPLICATIONS <b>RW Nesto</b> (Burlington, MA, USA)	125
4:35 PM - 4:55 PM	ABDOMINAL OBESITY AND METABOLIC SYNDROME: IMPLICATIONS FOR ASSESSMENT AND MANAGEMENT OF GLOBAL CARDIOMETABOLIC RISK <b>HB Brewer, Jr.</b> (Washington, DC, USA)	*126
4:55 PM - 5:00 PM	CLOSING REMARKS <b>J-P Després</b> (Quebec, QC, Canada)	-

WORKSHOP II-6  
ROOM 304

**Ankle Brachial Index, Pulse Wave Velocity and Other Imaging Modalities**

*Chairs: MH Criqui (La Jolla, CA, USA), J Vita (Boston, MA, USA)*

<b>Time</b>	<b>Presentation</b>	<b>Publication No.</b>
3:30 PM - 3:45 PM	ASSESSING ATHEROSCLEROSIS WITH THE ANKLE-BRACHIAL INDEX (ABI) <i>MH Criqui (La Jolla, CA, USA)</i>	127
3:45 PM - 4:00 PM	EVALUATION OF ENDOTHELIAL DYSFUNCTION <i>J Vita (Boston, MA, USA)</i>	128
4:00 PM - 4:15 PM	UTILITY OF THE AUTOMATIC MEASUREMENT OF THE ARTERIAL PRESSURE AS SCREENING AND DIAGNOSIS OF PERIPHERAL ARTERIAL DISEASE <i>C Sanclemente, A Pedragosa, X Pinto, E Corbella, O Mascaro (Barcelona, Spain and Vic, Spain)</i>	129 YIA
4:15 PM - 4:30 PM	ETHNIC DIFFERENCES IN ANKLE BRACHIAL INDEX ARE PRESENT IN INDIVIDUALS WITHOUT PERIPHERAL ARTERIAL DISEASE <i>S Singh, K Bailey, I Kullo (Rochester, MN, USA)</i>	130
4:30 PM - 4:45 PM	VELOCITY VECTOR ULTRASOUND IMAGING OF COMMON CAROTID ARTERY WALL MOTION PREDICTS ONE YEAR CARDIOVASCULAR OUTCOME IN PATIENTS WITH SUSPECTED CARDIOVASCULAR DISEASE <i>S Svedlund, C Eklund, P Robertsson, R Volkmann, L-M Gan (Gothenburg, Sweden and Molndal, Sweden)</i>	131 YIA
4:45 PM - 5:00 PM	ARTERIAL FUNCTION IN PATIENTS WITH INHERITED DYSLIPIDEMIAS <i>C Masoura, C Pitsavos, I Skoumas, K Aznaouridis, C Vlachopoulos, C Stefanadis (Athens, Greece)</i>	132
5:00 PM - 5:15 PM	HEMODYNAMIC AND HEMORHEOLOGICAL FEATURE INVESTIGATION IN RIGHT CORONARY ARTERY STENOSIS WITH 83% SEVERITY <i>HS Ji, M Kang, KC Kim (Busan, Korea and Seoul, Korea)</i>	133
5:15 PM - 5:30 PM	CAROTID INTIMA MEDIA THICKNESS AS A MEASURE OF CARDIOVASCULAR DISEASE BURDEN IN NIGERIAN AFRICANS WITH DIABETES MELLITUS AND HYPERTENSION <i>B Okeahialam, B Alonge, S Pam, F Puepet (Jos, Nigeria)</i>	134

WORKSHOP II- 7  
ROOM 310

**Lipoprotein Metabolism: Integration of Lipoprotein Metabolism**

*Chairs: HH Barrett (Perth, Australia), MW Huff (London, ON, Canada)*

Time	Presentation	Publication No.
3:30 PM - 3:45 PM	VIEWING LIPOPROTEIN METABOLISM FROM DIFFERENT PERSPECTIVES: INTEGRATION, INDIVIDUAL AND POPULATIONS <i>HH Barrett (Perth, Australia)</i>	135
3:45 PM - 4:00 PM	NARINGENIN PREVENTS THE DYSLIPIDEMIA, APOB OVERPRODUCTION AND HYPERINSULINEMIA IN LDL-RECEPTOR NULL MICE WITH DIET-INDUCED INSULIN RESISTANCE <i>E Mulvihill, E Allister, B Sutherland, R Hegele, MW Huff (London, ON, Canada)</i>	136
4:00 PM - 4:15 PM	KINETICS OF APOB-CONTAINING LIPOPROTEINS: AN UPDATE <i>K Ikewaki (Tokorozawa, Japan)</i>	137
4:15 PM - 4:30 PM	LIPOPROTEIN METABOLISM THROUGH THE LOOKING GLASS: INTEGRATING METABOLISM WITH STABLE ISOTOPE TRACERS <i>G Watts (Perth, Australia)</i>	138
4:30 PM - 4:45 PM	LIPOPROTEIN KINETICS IN SUBJECTS WITH LIPOPROTEIN LIPASE (LPL) GENE MUTATIONS <i>E Ooi, D Sprecher, E Schaefer, M Diffenderfer, N Matthan, H Barrett (Perth, Australia, King of Prussia, PA, USA and Boston, MA, USA)</i>	139
4:45 PM - 5:00 PM	REAL-TIME MAGNETIC RESONANCE IMAGING AND QUANTIFICATION OF LIPOPROTEIN METABOLISM IN VIVO USING NANOCRYSTALS <i>O Bruns, H Itrich, U Tromsdorf, U Beisiegel, J Heeren (Hamburg, Germany)</i>	140 YIA
5:00 PM - 5:15 PM	TWO MUTATIONS IN <i>GPIHBP1</i> CAUSE SEVERE CHYLOMICRONEMIA AND PROVIDE EVIDENCE FOR A CRITICAL ROLE OF GPIHBP1 IN HUMAN TRIGLYCERIDE METABOLISM <i>R Franssen, A Beigneux, J Hertecant, P Gin, M Weinstein, J Kastelein, A Bensadoun, L Fong, S Young, G Dallinga-Thie (Amsterdam, The Netherlands, Los Angeles, CA, USA, Al Ain, United Arab Emirates and Ithaca, NY, USA)</i>	141 YIA
5:15 PM - 5:30 PM	HUMAN CETP AGGREGATES ATHEROSCLEROSIS BY INCREASING VLDL-CHOLESTEROL RATHER THAN BY DECREASING HDL-CHOLESTEROL IN APOE*3-LEIDEN MICE <i>J de Vries-van der Weij, K Toet, S Zadelaar, LM Havekes, T Kooistra, PCN Rensen (Leiden, The Netherlands)</i>	142

WORKSHOP II-8  
ROOM 311

**Basic Science and Vascular Biology: Models of Atherosclerosis**

Chairs: **LK Curtiss** (La Jolla, CA, USA), **B Paigen** (Bar Harbor, ME, USA)

Time	Presentation	Publication No.
3:30 PM - 3:45 PM	ENDOTHELIAL CELL TOLL-LIKE RECEPTOR EXPRESSION AND MACROPHAGE ACCUMULATION ARE INCREASED ONLY IN REGIONS OF DISTURBED BLOOD FLOW IN THE MOUSE AORTA <i>L Curtiss, M Richards, P Tobias (La Jolla, CA, USA)</i>	143
3:45 PM - 4:00 PM	DIFFERENCES IN HEALTH STATUS AFFECT ATHEROSCLEROSIS SUSCEPTIBILITY AMONG INBRED STRAINS OF MICE <i>B Paigen (Bar Harbor, ME, USA)</i>	144
4:00 PM - 4:15 PM	THE CENTRAL ROLE OF ACAT2 AND CHOLESTERYL OLEATE IN ATHEROSCLEROSIS <i>L Rudel, J Sawyer, M Wilson, T Bell (Winston-Salem, NC, USA)</i>	145
4:15 PM - 4:30 PM	ANTIBODY BLOCKING OF ASP-C5L2 INTERACTIONS INCREASES ENERGY EXPENDITURE <i>K Cianflone, S Paglialunga, C Roy, W Cui (Quebec, QC, Canada)</i>	146
4:30 PM - 4:45 PM	ChREBP MEDIATES THE DEVELOPMENT OF HEPATIC STEATOSIS IN THE APGAT2 DEFICIENT MICE <i>V Cortés, A Agarwal, A Garg, J Horton (Dallas, TX, USA)</i>	147 YIA
4:45 PM - 5:00 PM	OCCCLUSIVE CORONARY ARTERIAL ATHEROSCLEROSIS (OCAA) AND MYOCARDIAL INFARCTION (MI) IN PAIGEN-DIET FED PDZK1/APOE DOUBLE KNOCKOUT (DKO) MICE <i>A Yesilaltay, K Daniels, R Pal, M Krieger, O Kocher (Cambridge, MA, USA and Boston, MA, USA)</i>	148
5:00 PM - 5:15 PM	ACCELERATED ATHEROSCLEROSIS WITH 11 $\beta$ -HSD2-DEFICIENCY IS ASSOCIATED WITH INCREASED INFLAMMATION IN EARLY STAGES OF PLAQUE DEVELOPMENT <i>D Armour, G Deuchar, K Chapman, Y Kotelevtsev (Edinburgh, UK)</i>	149 YIA
5:15 PM - 5:30 PM	SELECTIVE DEPLETION OF Foxp3+ REGULATORY T CELLS EXACERBATES EXPERIMENTAL ATHEROSCLEROSIS IN MICE <i>N Gerdes, R Klingenberg, D Strothoff, T Sparwasser, K Lahl, G Hansson (Stockholm, Sweden, Hannover, Germany and München, Germany)</i>	150 YIA